Today’s Research Reports on Trending Tickers: Oragenics and ACADIA Pharmaceuticals
U.S. equities remained bearish on Thursday as worries over rising interest rate and sell-off in technology shares pressure major markets to lower. The Dow Jones Industrial Average declined 2.13 percent to close at 25,052.83, losing 1,378 points in 2 days. S&P 500 Index decreased 2.06 percent to close at 2,728.37 and the Nasdaq Composite Index closed down 1.25 percent to close at 7,329.06. All major indexes finished below their 200-day moving average.
The market losses are “a reaction from investors finally realizing we are in a higher interest-rate environment, and given the elevated level of stocks, market participants were likely looking for a reason to sell,” said Charlie Ripley, senior investment strategist for Allianz Investment Management. “Higher interest rates typically bring on tighter financial conditions which could dampen growth going forward and equity markets are reacting to that.” He added, “we are witnessing the repercussions in the markets as the Fed takes the punch bowl away from the party.”
RDI Initiates Coverage on:
ACADIA Pharmaceuticals Inc.
Oragenics’ stock jumped 28.85% Thursday, to close the day at $1.34. The stock recorded a trading volume of 16,375,186 shares, which was above its three months average volume of 6,097,516 shares. In the last year, Oragenics’ shares have traded in a range of 0.38 – 4.70. The share price has gained 252.63% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $0.80 is below its 200-day moving average of $1.11. Shares of Oragenics have gained roughly 204.55 percent in the past month and are down 41.74 percent year-to-date.
Access RDI’s Oragenics, Inc. Research Report at:
On Thursday, shares of ACADIA Pharmaceuticals recorded a trading volume of 2,462,579 shares, which was below the three months average volume of 2,808,523 shares. The stock ended the day 3.71% higher at $20.99. The share price has fallen 44.76% from its 52 week high with a 52 week trading range of 12.77 – 38.00. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $17.02 is below its 200-day moving average of $17.21. Shares of ACADIA Pharmaceuticals have gained roughly 55.6 percent in the past month and are down 30.29 percent year-to-date.
Access RDI’s ACADIA Pharmaceuticals Inc. Research Report at:
Our Actionable Research on Oragenics, Inc. (NYSEAMERICAN:OGEN) and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.